TEVA - Teva Pharmaceutical Industries Limited

NYSE - NYSE Delayed Price. Currency in USD
10.20
-0.42 (-3.95%)
At close: 4:02PM EST
Stock chart is not supported by your current browser
Previous Close10.62
Open10.67
Bid10.21 x 3200
Ask10.24 x 27000
Day's Range10.15 - 10.70
52 Week Range6.07 - 20.21
Volume15,848,180
Avg. Volume19,107,293
Market Cap11.218B
Beta (5Y Monthly)1.82
PE Ratio (TTM)N/A
EPS (TTM)-3.77
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateNov 25, 2017
1y Target Est8.39
  • New antibiotics struggle to generate sales, pharma companies hurt
    Yahoo Finance Video

    New antibiotics struggle to generate sales, pharma companies hurt

    Pharmaceutical companies struggle to generate sales as doctors prescribe new anti-biotic, resistant superbugs sparingly. Yahoo Finance's On The Move panel break down the latest developments.

  • Business Wire

    Teva to Host Conference Call to Discuss Fourth Quarter 2019 Financial Results and 2020 Financial Guidance at 8 a.m. ET on February 12, 2020

    Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that it will issue a press release on its fourth quarter and full year 2019 financial results, as well as on its financial guidance for 2020, on Wednesday, February 12, 2020 at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET.

  • Moody's

    Teva Pharmaceutical Finance Netherlands IV BV -- Moody's announces completion of a periodic review of ratings of Teva Pharmaceutical Industries Ltd

    Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Teva Pharmaceutical Industries Ltd and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers. Since 1 January 2019, Moody's practice has been to issue a press release following each periodic review to announce its completion.

  • Endo Up on Opioid Abuse Settlement Agreement With Oklahoma
    Zacks

    Endo Up on Opioid Abuse Settlement Agreement With Oklahoma

    Endo (ENDP) settles an ongoing opioid-abuse litigation issue with the state of Oklahoma for $8.75 million.

  • Bristol-Myers Squibb's Stock Could Soar to New All-Time Highs This Quarter
    TheStreet.com

    Bristol-Myers Squibb's Stock Could Soar to New All-Time Highs This Quarter

    During the ' Lightning Round' of Mad Money Thursday night, Jim Cramer weighed in on Teva Pharmaceuticals : "No. We have Bristol-Myers Squibb , why do we need Teva?" Let's revisit the charts of BMY to see if the bulls can push BMY to new all-time highs. In this daily bar chart of BMY, below, we can see that prices have made a strong move up from the middle of July. The On-Balance-Volume (OBV) line made a double bottom in April and July and shows improvement to the middle of November.

  • Business Wire

    Teva to Present at the 38th Annual J.P. Morgan Healthcare Conference

    Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that President & CEO Kåre Schultz will present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, California on Monday January 13, 2020. The presentation will begin at 10:30 A.M. Pacific Time (1:30 P.M. Eastern Time), and a Q&A session will follow the presentation at 11:00 A.M. Pacific Time (2:00 P.M. Eastern Time).

  • Teva agrees to pay $54M to settle whistleblower lawsuit over speaker programs
    American City Business Journals

    Teva agrees to pay $54M to settle whistleblower lawsuit over speaker programs

    The whistleblower lawsuit alleges the pharmaceutical manufacturer was making improper payments to doctors to get them to write prescriptions for two Teva products.

  • Pfizer Stock Is A Top Pharma Company — But Should You Buy It?
    Investor's Business Daily

    Pfizer Stock Is A Top Pharma Company — But Should You Buy It?

    Pfizer stock tumbled below other pharma stocks on key metrics in 2019. Recent news has been upbeat with a drug approval and acquisitions. But is Pfizer stock a buy right now?

  • Jeff Clark’s Market Minute: These Stocks Will Carry the Market in 2020
    InvestorPlace

    Jeff Clark’s Market Minute: These Stocks Will Carry the Market in 2020

    2019 was a great year for the stock market - one of the strongest years ever.Source: Shutterstock And typically, following that sort of performance, the next year is great too.So, while nothing is ever guaranteed when it comes to the market… the odds are pretty good 2020 will be another bullish year.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 10 2019 Winners That Will Be 2020 Losers But - and this is important to understand - we likely won't see that great performance in the exact same sectors…Semiconductor stocks were the top performers in 2019. Advanced Micro Devices (NASDAQ:AMD) gained 152%. Lam Research (NASDAQ:LRCX) popped 116% higher. Applied Materials (NASDAQ:AMAT) jumped 88%.But, it probably won't be the big winners of 2019 that lead the market higher this year.Instead, traders should look for the laggards to play catch-up.No doubt, 2019 was a momentum-driven market. Strong stocks got stronger throughout the year. Weak stocks got weaker. And, that trend accelerated in December as institutions and money managers engaged in the art of "window dressing."They bought more of the market's best-performing stocks so when they published their holdings at the end of the year, they could show investors they owned the markets best performers. And, they sold off the worst-performing stocks so they could show investors their limited exposure to bad performers.That action has created one of the widest valuation discrepancies between growth stocks and value stocks since 2000.You see, on a relative basis, growth stocks are historically expensive today… and value stocks are historically cheap.AMD, for example, trades at 44 times 2020 earnings estimates. That's quite richly valued compared to the S&P 500, which trades for about 18 times 2020 earnings estimates.Meanwhile, value stocks like Teva Pharmaceuticals (NYSE:TEVA), which trades at less than 4 times 2020 earnings estimates, are historically cheap.Granted… TEVA has its issues, and the outlook is cloudy. And, AMD is firing on all cylinders and the future is shining bright.But gosh… is AMD really worth ten times the earnings multiple of TEVA - or any other company that actually has earnings?My point is… the valuation gap between growth and value has expanded to a historically wide level. Growth stocks are trading for historically high valuations. Value stocks are historically cheap.If the broad stock market is going to continue higher in 2020, then it's going to be fueled by a "catch-up" rally in the value stocks. Traders should be looking for the undervalued and underappreciated names of 2019 to lead the market higher this year.Best regards and good trading,Jeff ClarkP.S. If you ask my friend and colleague Teeka Tiwari, there's another sector that should do very well in 2020…But, it's not in the stock market.Teeka says that by acting on this idea, you could potentially pay for your whole retirement after one specific day this year.If you're interested, just click right here and get the story straight from Teeka. But don't wait too long… This opportunity closes for good before the end of January. Reader MailbagToday a new subscriber thanks Jeff for his frequent communication…Jeff, though I'm fairly new to your services and have hardly placed any trades - the amount of communication you have is awesome. The transparency of your thoughts, daily, about where you see potential trades going is bold.No one gets everything right all the time, but you actually put yourself out there consistently. I think it'll make me a better trader by just reading your thoughts you share consistently.- MarkAnd another subscriber shares his recent gains using Jeff's Breakout Alert strategy…Thank you for one of your most recent Breakout Alert trade recommendations… I was able to close it with over 70% gains!On top of another recent trade that brought me 30% gains, this makes the Breakout Alert my favorite subscription, next to Delta Direct and Delta Report. I stopped using all my other subscriptions.I like the way you explain the trades, how you follow up with the trades, and your approach to the trades.The Jeff Clark Mobile app is practical, and I use it every day. I look forward to reading your report every morning as well as updates throughout the day.- GermanAnd one more reports on their experience using the new Jeff Clark Mobile app…Jeff, this latest app is working simply awesome for me. I used to use the text alerts for notifications then log on and look what was just posted.This latest revision of your app requires only my fingerprint without having to fumble passwords. PLUS, it gives the latest of each subscription, so at first glance I only get what I haven't seen.I'm so excited because I get a better jump on your recommended trade at each post. If I want to look at something that's aging in a portfolio, I can always use the web browser for that.Thanks, Jeff, for your relentless improvements!- PaulIf you haven't already, make sure to download the Jeff Clark Trader mobile app (here for iPhone and here for Android). And if you like what you see… or even think it could use some work… consider leaving a review on either app store.As always, thank you for your thoughtful emails. We look forward to reading them every day. Keep them coming to feedback@jeffclarktrader.com. In Case You Missed It…The Final Phase of the 5G Boom: How to Stake Your Claim Before It's Too Late"The biggest 5G growth phase is set to begin soon. Up to $12.3 trillion will be unleashed, and dozens of tiny stocks could soar. Join me as I reveal my script for finding the best 5G plays before they go parabolic." - 5G expert Jeff BrownMore information here. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 2019 Winners That Will Be 2020 Losers * 5-Year Returns for 5 Dow Jones Stocks Entering 2020 * 5 Semiconductor Stocks to Buy for Big Gains In 2020 The post Jeff Clark's Market Minute: These Stocks Will Carry the Market in 2020 appeared first on InvestorPlace.

  • Stay on the Sidelines as the Future Looks Potentially Bleak for Teva Stock
    InvestorPlace

    Stay on the Sidelines as the Future Looks Potentially Bleak for Teva Stock

    Teva (NYSE:TEVA) may be up over 60% from its 52-week low, but Teva stock is not out of the woods yet in terms of its headwinds.Source: JHVEPhoto / Shutterstock.com High debt, its exposure to the opioid crisis, as well as its current price-fixing scandal, offer investors a cocktail of risk. Certainly, the market has priced these risks into shares.Yet, valuation-wise, shares aren't exactly cheap. Despite these headwinds, shares trade at higher Enterprise Value/EBITDA ratio than generic drug peer Mylan N.V. (NASDAQ:MYL). So, what's the play with Teva Pharmaceuticals? With the recent run-up, it's clear the easy money's already been made.InvestorPlace - Stock Market News, Stock Advice & Trading TipsPositive developments could push shares higher. Short interest is not particularly high. On the other hand, upside looks like a challenge. Until TEVA can resolve both its debt and legal issues, expect the stock to stay in limbo. * 7 Stocks to Buy for January and Beyond A strong market could also be propping up Teva stock. With these factors in mind, let's dive in, and see why TEVA is a hot mess best avoided. Just When I Thought I Was Out…Last fall, opioid-exposed drug makers thought they had a solution to their legal liabilities. Teva Pharmaceuticals partnered with Johnson & Johnson (NYSE:JNJ) and three other defendants to cut a deal with prosecutors across the country. In this deal, the company would only get a slap on the wrist: $250 million cash, along with $23 billion worth of opioid addiction-treatment drugs over 10 years.But state and local prosecutors said, "no dice." This settlement required sign-on en-masse from thousands of legal eagles. Very few seemed willing to settle. Despite the push-back, CEO Kare Schultz remained confident sign-off would happen by the end of 2019.But hindsight is 2020. Literally. This year, state and local attorneys general are going in for the kill. Federal prosecutors will join in as well. Teva Pharmaceuticals may have thought they were out, but prosecutors pulling them back in. And why not? The opioid crisis is red meat for attorneys general looking to make a name for themselves.Investors have deluded themselves into thinking the opioid crisis is priced into shares. Pay a little fine, give out some suboxone, everything's copacetic. But given how things are playing out, expect the worst until a new settlement proposal is on the table.But that's not all! Back in December, InvestorPlace's David Moadel broke down Teva's exposure to a generic drug price-fixing scandal. 44 states are going after Teva Pharmaceuticals and other generic producers. Their goal? To claw back billions that resulted from the collusion.There's no ballpark estimate for this liability. But the last thing Teva stock needs is another anvil over its head. Add in a high debt burden, and the company remains a minefield. Can TEVA Get Its House in Order?It's tough to quantify the legal liabilities hanging over Teva stock. But we can quantify their heavy debt burden. As of September 30, 2019, TEVA had around $27 billion in outstanding debt. In the short run, Teva may be okay in terms of refinancing or paying off debt coming due. Thanks to free cash flow generation, along with a recent refinancing, they have the funds to retire maturing debt.Analyst consensus does not project revenue or earnings growth over the next year. But if Teva Pharmaceuticals can hold steady, they could generate the cash flow necessary to continue whittling down outstanding debt.To move the needle, the company needs to bring cash flow back to prior levels. A small bump up in sales, along with continued cost reduction, could achieve this goal. Doing this will bring their head above water. With more cash to pay down debt and handle legal liabilities, Teva stock could skyrocket.Yet, at the current valuation, this upside could be priced into shares. As mentioned above, shares trade at a higher EV/EBITDA ratio (8.7) than peer Mylan (EV/EBITDA of 6.7). Both companies trade at similar non-GAAP price-to-earnings (P/E) ratios. Teva stock trades for 4.1 times forward earnings. Mylan trades for 4.7 times forward earnings.Once legal risks are mitigated, the company could even benefit from multiple expansion. The big pharma names trade at EBITDA multiples above 10. I don't see shares trading at a premium to these names, but the discount should tighten once investors are more confident in Teva's future. Take Your Time Before Buying TEVA StockThis year could make or break Teva stock. If the company can handle its debt load and settle legal liabilities for as little as possible, shares could skyrocket. Conversely, shares could fall back to prior levels (around $6/share) or less, if legal liabilities are greater than estimated.With shares rebounded, now may not be the time to enter Teva stock. Wait to see how upcoming opioid trials play out. If shares pull back to prior price levels, a buying opportunity may emerge. But for now, the risks do not match up with potential upside.As of this writing, Thomas Niel did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Stocks to Buy for January and Beyond * 7 Excellent Value Stocks to Buy for 2020 * 5 Hot Housing Stocks That Could Stay Hot in 2020 The post Stay on the Sidelines as the Future Looks Potentially Bleak for Teva Stock appeared first on InvestorPlace.

  • Axsome's (AXSM) Migraine Drug Meets Goals in Late-Stage Study
    Zacks

    Axsome's (AXSM) Migraine Drug Meets Goals in Late-Stage Study

    Axsome's (AXSM) migraine drug meets two regulatory, co-primary endpoints in a phase III study.

  • Will J&J be Able to Overcome Its Legal Troubles in 2020?
    Zacks

    Will J&J be Able to Overcome Its Legal Troubles in 2020?

    Here we discuss the growth potential of J&J's (JNJ) stock in 2020.

  • Barrons.com

    Investors Have Been Optimistic About Opioid Litigation. It’ll Still Be an Issue in 2020.

    For investors and the companies facing these trials, the opioid litigation isn’t going anywhere in 2020.

  • Is Mylan (MYL) Doomed to Witness a Terrible 2020 Too?
    Zacks

    Is Mylan (MYL) Doomed to Witness a Terrible 2020 Too?

    As Mylan (MYL) remained plagued with challenges in 2019, we take an insight into whether or not, the next year holds any promise for the company.

  • Allergan (AGN) Gets FDA Approval for Migraine Drug Ubrelvy
    Zacks

    Allergan (AGN) Gets FDA Approval for Migraine Drug Ubrelvy

    Allergan (AGN) gets FDA nod for Ubrelvy for the acute treatment of migraine with or without aura in adults.

  • Teva Pharmaceutical Industries Ltd. (TEVA) Outpaces Stock Market Gains: What You Should Know
    Zacks

    Teva Pharmaceutical Industries Ltd. (TEVA) Outpaces Stock Market Gains: What You Should Know

    Teva Pharmaceutical Industries Ltd. (TEVA) closed the most recent trading day at $9.97, moving +1.73% from the previous trading session.

  • GlobeNewswire

    NexImmune Appoints Sol Barer as Chairman of the Board of Directors

    GAITHERSBURG, Md., Dec. 16, 2019 -- NexImmune, a clinical-stage biopharmaceutical company developing novel immune-therapeutics based on a proprietary Artificial Immune.

  • Bernard Horn Goes 2 for 2 in 3rd Quarter
    GuruFocus.com

    Bernard Horn Goes 2 for 2 in 3rd Quarter

    Guru invests in Canadian bank and an Austrian paper manufacturer Continue reading...

  • Teva Stock Is Nothing but Trouble after Legal Issues
    InvestorPlace

    Teva Stock Is Nothing but Trouble after Legal Issues

    Low-priced pharmaceutical stocks are known troublemakers, and emblematic of the pharma niche is Teva (NYSE:TEVA). Over the course of its history, TEVA stock has taken shareholders on a ride from a few cents to the $70 level, only to retreat back below $10.Source: JHVEPhoto / Shutterstock.com However, a government crackdown on alleged opioid-dealing firms has cemented TEVA's reputation as an outlaw stock. But some folks persist in buying the shares and hoping for a recovery -- both in reputation and in price action.Just this year, traders have watched as Teva stock slid from $20 to less than half of that. So, given its unpredictability, are Teva Pharmaceuticals shares a prime dip-buy opportunity? Or are they just a slow-motion train wreck?InvestorPlace - Stock Market News, Stock Advice & Trading Tips A Teva SubpoenaWhen I coach up-and-coming traders, one basic principle I tell them is to not fight the government. That's a battle you won't win.In other words: if there's a company on your watch list with government issues, pick a less worrisome candidate.First off, you've got the U.S. government's crackdown as federal authorities named a half-dozen opioid-dealing pharmaceutical companies in an investigation -- and of course, Teva's on the hit list. Emboldened by this, state and city governments following suit (literally) and initiating their own legal actions would not surprise me. * 7 Energy Stocks That Are Still Worth Buying In 2020 News of the federal probe sent TEVA stock shares tumbling nearly 8% in a single trading session, reminding traders that the government can and will smash errant pharma firms. And as the criminal probe drags on, public perception of Teva and other pharmaceutical companies will likely continue to suffer. A Price-fixing ImbroglioSticking to the "you can't battle the government and win" theme, we can now turn our attention to the far-reaching price-fixing scandal.At this point, 44 states suing 20 generic-drug manufacturers (including Teva, naturally) were named in what Connecticut Attorney General William Tong has dubbed "the largest cartel case in the history of the United States." And while 20 firms were identified, Teva has the starring role and the 524-page lawsuit reads like a tabloid:"The Defendants exploited their interactions at various and frequent industry trade shows, customer conferences and other similar events, to develop relationships and sow the seeds for their illegal agreements. These anticompetitive agreements are further refined and coordinated at regular 'industry dinners,' 'girls' nights out,' lunches, parties, golf outings, frequent telephone calls, e-mails and text messages."The damage to Teva is over, and it could take years before the company and its shareholders recover.And frankly, my sympathy for the company runs thin. Generic drug makers should help lower prices, not raise them, and Teva's illicit activity impacts all of us. Quoting the lawsuit again:"The anticompetitive conduct -- schemes to fix and maintain prices, allocate markets and otherwise thwart competition -- has caused, and continues to cause, significant harm to the United States healthcare system, which is ongoing."The lawsuit also notes that "Defendant Teva is a consistent participant in the conspiracies identified in this Complaint, but the conduct is pervasive and industry-wide," indicating a deep-rooted issue that merits federal-level intervention.Reform in this area would hopefully benefit the public, but could pose a potential problem for shareholders. Teva Stock? See ya!I won't go so far as to consider the company's legal issues an existential threat. However, they ought to deter any thoughtful investor from taking a long position in Teva stock. Maybe the share price will recover or maybe it won't. But until the company appeases regulators and restores its reputation, I'd say Teva is nothing but trouble.As of this writing, David Moadel did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Energy Stocks That Are Still Worth Buying In 2020 * 7 Strong Stocks to Buy That Won Q3 Earnings * 5 Safety Stocks to Buy Without Trade War Exposure The post Teva Stock Is Nothing but Trouble after Legal Issues appeared first on InvestorPlace.

  • Did Hedge Funds Drop The Ball On Teva Pharmaceutical Industries Limited (TEVA) ?
    Insider Monkey

    Did Hedge Funds Drop The Ball On Teva Pharmaceutical Industries Limited (TEVA) ?

    We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds' top 3 stock picks returned 41.7% this year and beat […]

  • GuruFocus.com

    Bayer and Teva Double Down on Worst M&A Deals of Decade

    The companies both hit the dubious roster twice, but are joined by many of the biggest names in the drug industry Continue reading...

  • Axsome Narcolepsy Candidate Meets Phase II Goal, Stock Up
    Zacks

    Axsome Narcolepsy Candidate Meets Phase II Goal, Stock Up

    Axsome (AXSM) announces data from a phase II study evaluating AXS-12 in narcolepsy patients, demonstrating statistically significant reduction in weekly cataplexy attacks.

  • J&J's (JNJ) New Tests Reveal No Asbestos in Baby Powders
    Zacks

    J&J's (JNJ) New Tests Reveal No Asbestos in Baby Powders

    J&J (JNJ) says that two third-party labs conducted 155 tests on samples of its baby powders. All these tests confirm that the talc does not contain asbestos, a known carcinogen.

  • Mylan (MYL) Launches Herceptin Biosimilar Ogivri in the US
    Zacks

    Mylan (MYL) Launches Herceptin Biosimilar Ogivri in the US

    Mylan (MYL) launches Ogivri, a biosimilar of Roche's blockbuster breast cancer drug, Herceptin (trastuzumab), in the United States.

  • Possible criminal probe undermines recovery in opioid stocks since global legal settlement announced
    MarketWatch

    Possible criminal probe undermines recovery in opioid stocks since global legal settlement announced

    The stock prices of opioid drugmakers and distributors fell this week after news of a possible federal criminal probe, eroding many of the gains made in the weeks since a global settlement resolving opioid litigation was first announced.